New cocktail aims to shrink stomach tumors
NCT ID NCT07356466
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests whether adding two drugs—pucotenlimab (an immunotherapy) and lenvatinib (a targeted therapy)—to standard chemotherapy (SOX) can shrink tumors better than chemotherapy alone in people with advanced HER2-negative stomach or gastroesophageal junction cancer. About 100 participants will be randomly assigned to one of the two treatment groups. The main goal is to see how many patients have their tumors shrink significantly.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pucotenlimab (an immunotherapy drug) combined with lenvatinib (a targeted therapy) and SOX chemotherapy (oxaliplatin plus S-1)
What this could lead to
If successful, this combination could offer a new, more effective treatment option for people with advanced stomach cancer that is not curable with current therapies.
What could go wrong
This is a very early (Phase 1) and small trial, so results may not be conclusive. The added drugs may cause more side effects without improving outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTRIC (STOMACH) CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, 350001, China